Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > BUSINESS
BUSINESS
- HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
March 31, 2016
- Eisai Transfers Thrombocytopenia Drug to US Investment Firm
March 31, 2016
- Janssen Files Stelara for Crohn’s Disease
March 31, 2016
- EA Pharma to Start Up with 440 Sales Reps, Offer 24 Products
March 31, 2016
- Kyorin, Kissei to Jointly Develop, Market OAB Treatment
March 31, 2016
- Santen Gets Worldwide Rights to Ono’s FP and EP3 Dual Receptor Agonist
March 31, 2016
- Shionogi Files Japan, US NDAs for Naldemedine for Opioid-Induced Constipation
March 31, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Astellas, Mitsubishi Tanabe to Share Compound Libraries
March 30, 2016
- In a Setback, FDA Rebuffs Label Expansion for Takeda’s Brintellix
March 30, 2016
- PeptiDream, Asahi Kasei Pharma Forge Research Collaboration
March 29, 2016
- Mylan Japan Offers Severance Package for 110 Sales Reps
March 29, 2016
- ASKA Shoots for Group Annual Sales of 70 Billion Yen in Five Years
March 29, 2016
- Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma
March 29, 2016
- Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
March 28, 2016
- IP High Court Rules in Favor of Chugai in Oxarol Patent Suit
March 28, 2016
- Lilly Joins Hands with NCC on Biomarkers for Advanced Gastric Cancer
March 28, 2016
- Global PIII for Xtandi Launched for Hormone Sensitive Prostate Cancer: Astellas
March 28, 2016
- Takashi Nakamura to Be Promoted to President of Qol
March 25, 2016
- Public Knowledge-Based Application Filed for Colchicine for Familial Mediterranean Fever
March 25, 2016
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…